BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 26914830)

  • 1. Alopecia areata and health-related quality of life: a systematic review and meta-analysis.
    Rencz F; Gulácsi L; Péntek M; Wikonkál N; Baji P; Brodszky V
    Br J Dermatol; 2016 Sep; 175(3):561-71. PubMed ID: 26914830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review.
    Liu LY; King BA; Craiglow BG
    J Am Acad Dermatol; 2016 Oct; 75(4):806-812.e3. PubMed ID: 27436156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data.
    Shi Q; Duvic M; Osei JS; Hordinsky MK; Norris DA; Price VH; Amos CI; Christiano AM; Mendoza TR
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S49-50. PubMed ID: 24326555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety.
    Russo PM; Fino E; Mancini C; Mazzetti M; Starace M; Piraccini BM
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):608-611. PubMed ID: 30394586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in patients with alopecia areata: Results of a Japanese survey with norm-based comparisons.
    Ito T; Kamei K; Yuasa A; Matsumoto F; Hoshi Y; Okada M; Noto S
    J Dermatol; 2022 Jun; 49(6):584-593. PubMed ID: 35342979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes.
    Chernyshov PV; Tomas-Aragones L; Finlay AY; Manolache L; Marron SE; Sampogna F; Spillekom-van Koulil S; Pustisek N; Suru A; Evers AWM; Salavastru C; Svensson A; Abeni D; Blome C; Poot F; Jemec GBE; Linder D; Augustin M; Bewley A; Salek SS; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1614-1621. PubMed ID: 34107093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata.
    Lai VWY; Chen G; Sinclair R
    J Dermatolog Treat; 2021 Mar; 32(2):250-257. PubMed ID: 31389731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical profile and impact on quality of life: seven years experience with patients of alopecia areata.
    Al-Mutairi N; Eldin ON
    Indian J Dermatol Venereol Leprol; 2011; 77(4):489-93. PubMed ID: 21727697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing quality of life in Alopecia areata patients in China.
    Qi S; Xu F; Sheng Y; Yang Q
    Psychol Health Med; 2015; 20(1):97-102. PubMed ID: 24628099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatric symptomatology and health-related quality of life in children and adolescents with alopecia areata.
    Bilgiç Ö; Bilgiç A; Bahalı K; Bahali AG; Gürkan A; Yılmaz S
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1463-8. PubMed ID: 24237476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review.
    Toussi A; Barton VR; Le ST; Agbai ON; Kiuru M
    J Am Acad Dermatol; 2021 Jul; 85(1):162-175. PubMed ID: 32561373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing quality of life, anxiety, depression, sleep disturbance, and associated factors in vitiligo and alopecia areata patients.
    Ghalamkarpour F; Araghi F; Tabari M; Moslemi Haghighi S; Pourgholi E
    J Cosmet Dermatol; 2024 May; 23(5):1808-1815. PubMed ID: 38169098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the alopecia areata symptom impact scale.
    Mendoza TR; Osei JS; Shi Q; Duvic M
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S51-2. PubMed ID: 24326557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability and validity of a measure to assess the health-related quality of life of women with alopecia areata.
    Rees H; Wall D; Bokhari L; Asfour L; Sinclair R
    Clin Exp Dermatol; 2023 Jun; 48(6):681-684. PubMed ID: 36806573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Illness perception in patients with androgenetic alopecia and alopecia areata in China.
    Yu NL; Tan H; Song ZQ; Yang XC
    J Psychosom Res; 2016 Jul; 86():1-6. PubMed ID: 27302539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review.
    Mostaghimi A; Napatalung L; Sikirica V; Winnette R; Xenakis J; Zwillich SH; Gorsh B
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):867-883. PubMed ID: 33770385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-Related Quality of Life, Depression, and Self-esteem in Patients With Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Huang CH; Fu Y; Chi CC
    JAMA Dermatol; 2021 Aug; 157(8):963-970. PubMed ID: 34232264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis.
    Mohan GC; Silverberg JI
    JAMA Dermatol; 2015 May; 151(5):522-8. PubMed ID: 25471826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and validity assessment of the revised Symptom Checklist 90 for alopecia areata patients in China.
    Tan H; Lan XM; Yu NL; Yang XC
    J Dermatol; 2015 Oct; 42(10):975-80. PubMed ID: 26072969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis.
    Lee HH; Gwillim E; Patel KR; Hua T; Rastogi S; Ibler E; Silverberg JI
    J Am Acad Dermatol; 2020 Mar; 82(3):675-682. PubMed ID: 31437543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.